SARADHA CHEXAL, MD
Cell: (561)-212-9831
E-mail: schexal@e-retina.net

CURRENT ADDRESS

Work:

Retina Consultants of Austin, PA
3705 Medical Parkway, Suite 410
Austin, Texas 78705
512-454-5851

Retina Consultants of Austin, PA
1880 Round Rock Avenue, Ste. 300
Round Rock, TX 78681
512-454-5851

Retina Research Center
3705 Medical Parkway, Ste 420
Austin, Texas 78705
512-454-0138

EMPLOYMENT

Retina Research Center — Austin, TX
September 2014-present

Brian B. Berger, M.D. and Associates — Austin, TX
Private practice- Retina — September 2014-present

FELLOWSHIP

JULES STEIN EYE INSTITUTE, UCLA — Los Angeles, CA
Retina — July 2013-2014

RESIDENCY

UNIVERSITY OF SOUTH FLORIDA — Tampa, FL
Dept. of Ophthalmology — July 2010 – July 2013

- Awarded Chief Resident 2012-2013

ST. VINCENT'S HOSPITAL MANHATTAN — New York, NY
Dept. of Internal Medicine — July 2009 – July 2010

- Medical internship

EDUCATION

NEW YORK MEDICAL COLLEGE — Valhalla, NY
M.D. — 2005 - 2009

- Awarded $15,000 grant from the Friends of the Congressional Glaucoma Caucus Foundation to start the NYMC chapter of the Student Sight Savers Program – provided free glaucoma screenings to the local community
- AOA Pathology / Microbiology tutor

UNIVERSITY OF FLORIDA — Gainesville, FL
B.S., Microbiology (cum laude) — 2002 – 2005

- UF Honors Program Scholarship – full tuition
- Graduated in 3 years

MANUSCRIPTS

- *Retinal Cavernous hemangioma and Arnold Chiari Malformation Type 1: a case report.* Lyons L, Chexal S. to be submitted to Retina today 2017.

- *En face OCT imaging in Multiple Evanescent White Dot Syndrome.* Chexal S, Sarraf D, Pichi F. Submitted.

- *Choroidal involvement in Acute Posterior Placoid Pigment Epitheliopathy.* Mrejen S, Chexal S, Sarraf D, Freund B. Osli Retina.2016.

- *ASRS abstract.* Chexal S, Sarraf D. 2016

- *Plaquenil toxicity and ideal body weight: a case series*. Iragavarapu S, Sanfilippo C, Sarraf D. To be submitted.

- *Gender and Hereditary Eye Disease: A Review.* Iragavarapu S, Gorin MB. Current Eye Research. August 2014.

- *Birdshot Retinochoroidopathy.* Iragavarapu, S. Grand Rounds Presentation. **www.eyewiki.com.** 2012 June 19.

- *Forme fruste anterior segment dysgenesis.* Abanitt MR, Romano A, Iragavarapu S, Budenz DL, Lee RK. Br J Ophthalmol. 2010 Aug 30.

- *ETX1 is over-expressed in the glaucomatous trabecular meshwork.* Iragavarapu S, Algeciras ME, Lee RK, Bhattacharya SK. Mol Vis 2009 Oct 16;15:2061-7.

- *ARVO* Abstract Title: Localized Expression of Disco-Interacting Protein 2 Homolog (Dip2A) in Human Eyes. Author block: *T.K. Lee, S. Iragavarapu, G. Gaidosh, R.K. Lee, S.K. Bhattacharya.* U. of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL. 2008.

CLINICAL RESEARCH

Sub-Investigator: Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd., CR29521 Stairway)

Sub-Investigator: A Phase II, Multicenter, Randomized, Active-Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd, GX28228 Ladder)

Sub-Investigator: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy (Acucela Inc., 4439-203)

Sub-Investigator: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122

Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration (Santen Inc., PAVE study)

Sub-Investigator: A Randomized, Double Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron Pharmaceutical, Inc, R910-3-AMD-1517 ONYX)

Sub-Investigator: A Multiple-Center, Multiple-Does, Randomized, Active Comparator-Controlled, Double-Masked, Parallel-Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmaokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (Genentech BP30099 Boulevard)

Sub-Investigator: Intravitreous Anti-VEGF Treatment for Prevention of Vision Threating Diabetic Retinopathy in Eyes at High Risk (DRCR Protocol W)

Sub-Investigator: Genes in Diabetic Retinopathy Project (DRCR Genetics)

Sub-Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Genentech BP29647 Avenue)

Sub-Investigator: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (DRCR Protocol S)

Sub-Investigator: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (DRCR Protocol V)

Sub-Investigator: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (DRCR Protocol U)

Sub-Investigator: A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Allegro Ophthalmics, LLC, DME 202B)

Sub-Investigator: An open-label single ascending dose and randomized double-masked, ranibizumab controlled, safety, tolerability, and efficacy study of intravitreal LMG324 in subjects with neovascular age-related macular degeneration (Alcon Research, LTD, LMG324-2201)

Sub-Investigator: A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (Alcon Research, LTD, CLG561-2201)

Principal Investigator: A Phase 4 Safety Study of IOP Signals Inpatients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG (Alimera Sciences, Inc., M-01-15-004)

Principal Investigator: Prospective, Multicenter Post-Approval Study (PAS) of Visioncare's Implantable Miniature Telescope (By Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration (VisionCare Ophthalmic Technologies, IMT-PAS-01)

Sub-Investigator: Clinical Study Protocol Phase 1 Dose Escalation and Expansion Study of DS-7080a in Subjects with Neovascular Age-Related Macular Degeneration (Daiichi Sankyo Pharma Development, DS7080-A-U101)

Sub-Investigator: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research, Ltd., RTH258-E003)

Sub-Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY – (Apellis Pharmaceuticals, Inc., POT-CP121614)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus *prn* Eylea® Compared to *prn* Eylea® Monotherapy in Neovascular AMD (Tyrogenex, Inc., X82-OPH-201)

Sub-Investigator: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration (StemCells, Inc., CL-AMD-201)

Sub-Investigator: Prospective, observational longitudinal study addressing Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time (DRCR AA)

Sub-Investigator: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research Ltd. RTH258-C001)

Sub-Investigator: A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic Therapeutics IT-002)

Sub-Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Astellas Pharma Europe B.V. VIDI)

Sub-Investigator: A randomized, parallel group, double-masked, active-controlled Phase 1/2 clinical trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis (Aciont, Inc. DSPV-201)

Sub-Investigator**:** A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patient with Geographic Atrophy Secondary to Age-Related Macular Degneration (Genentech GX29176 Chroma)

Sub-Investigator: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: A Multicenter, Prospective, Randomized Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 weeks with Intravitreal Aflibercept Every 4 weeks (SCORE2)

Sub-Investigator: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration (University of Virginia Department of Ophthalmology TOGA)

Sub-Investigator: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) (Panoptica PAN-90806)

Sub-Investigator: A Phase 2, Randomized, Active- Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema (Aerpio AKB-9778):

Sub-Investigator: Ocriplasmin Research to Better Inform Treatment (Thrombogenics TG-MV-018 ORBIT**)**

Sub-Investigator: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDG-F Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Ophthotech Corp. OPH1003)

Sub-Investigator: A prospective, Two Cohort, Single-Masked, Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (Alcon C-13-001 ESBA1008)

Sub-Investigator: An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing of Gevokizumab in Non-Infectious Intermediate, Posterior, or Pan- Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131Study (XOMA X052132)

Sub-Investigator: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (XOMA X052130)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment (XOMA X052131)